Christopher Sweeney

39PUBLICATIONS
294CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsLiquid biopsiesGenomics and transcriptomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 24, 2026
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.

|Sep 27, 2026
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial.

|Aug 21, 2026
APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.

|Jul 08, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

|Jun 26, 2026
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

|Apr 29, 2026
A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

Pageof 7

Frequent Collaborators

7 joint publications

Martin Stockler

7 joint publications

Ian D Davis

5 joint publications

Atish D Choudhury

5 joint publications

Silke Gillessen